Allergan - International Biopharmaceutical Industry

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Subsection - Oncology

Essential DMPK Strategies for IND Success

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

news

Allergan’s eye drug stacks up against Lucentis, but wider market still iffy

Allergan on Thursday touted data from two late-stage trials that showed a drug it in-licensed from a Swiss biotech proved non-inferior to Lucentis in the treatment...

20 July 2018 news Allergan | Drug

Continue Reading →

news

Allergan to sell off women’s health, anti-infective businesses

Allergan plans to sell its women's health and infectious disease units, aiming to shore up investor confidence and more narrowly focus the company amid a steady e...

1 June 2018 news Allergan | anti-effective

Continue Reading →

news

Saunders: All options remain on the table for Allergan

Brief: Allergan CEO Brent Saunders said Monday the Irish pharma is considering a wide range of business options, including further divestitures or a split of the ...